European Commission Approved Rinvoq for Pediatric Arthritis
The approval provides a new treatment option for children two years and older with active polyarticular juvenile idiopathic arthritis.
Updated on Sept. 30, 2026 in Arthritis
Live Poll
Do you support the authorization of new medical treatments for pediatric patients with chronic conditions?
The European Commission has authorized the use of Rinvoq for children aged two and older diagnosed with active polyarticular juvenile idiopathic arthritis. This approval is specifically intended for young patients who have not responded adequately to, or are intolerant of, previous disease-modifying antirheumatic drugs (DMARDs).
Why it matters
This regulatory decision expands treatment options for a chronic condition affecting an estimated 126,000 children in Europe, offering an alternative for those whose disease has not been controlled by conventional therapies. It provides a new path for managing the inflammation associated with this pediatric autoimmune disease.
The approval is based on the Phase 1 SELECT-YOUTH study, which evaluated the pharmacokinetics, safety, and efficacy of the drug in children aged two to under 18. Researchers observed therapeutic responses beginning at week 12, with continued improvements in response rates through week 48.
The players
European Commission
The executive branch of the European Union responsible for regulatory approvals of medical treatments.
The details
Rinvoq is now available in both 15 mg tablets and a new weight-based oral solution to accommodate younger patients. The treatment is indicated for polyarticular juvenile idiopathic arthritis, which is characterized by inflammation in five or more joints lasting at least six weeks, and is designed for those who have failed or cannot tolerate traditional DMARD treatments.
Timeline
Efficacy was observed in the study at week 12.
Response rates improved through week 48 of the study.
Health Landscape
This authorization follows the success of the SELECT-YOUTH clinical trial program in demonstrating the safety and efficacy of the medication for children. It adds to a growing list of 11 immune-mediated, inflammatory indications currently approved for this drug within the European Union.
Families of children with polyarticular juvenile idiopathic arthritis should discuss these new treatment options with their rheumatologist to determine if this medication is appropriate. It is important to review a child's prior experience with DMARDs and current joint health status before considering any changes to an existing care plan.
The takeaway
This approval provides a new oral treatment option for children suffering from persistent joint inflammation who have exhausted other standard therapies. Parents should consult with their child's pediatric specialist to understand the role of weight-based dosing and the clinical trial evidence.
Further reading
For more information on managing chronic joint inflammation, visit our Arthritis section.
Source note: This article includes information reported by PharmaTimes.
Live Poll
Do you support the authorization of new medical treatments for pediatric patients with chronic conditions?
